Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 8/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13208606 | 0.93 | CXCR1 (0.42) | CXCR1CXCR2 | |
| SCHEMBL13208652 | 0.91 | CXCR1 (0.37) | CXCR1CXCR2KMT2ASMN1; SMN2 | |
| SCHEMBL13208649 | 0.91 | CXCR1 (0.51) | CXCR1CXCR2KMT2ASMN1; SMN2 | |
| SCHEMBL13207718 | 0.89 | CXCR1 (0.35) | CXCR1CXCR2 | |
| SCHEMBL13208202 | 0.85 | CXCR1 (0.49) | CXCR1CXCR2 | |
| SCHEMBL13208419 | 0.85 | CXCR1 (0.46) | CXCR1CXCR2 | |
| SCHEMBL13208647 | 0.84 | CXCR2 (0.50) | CXCR1CXCR2KMT2ASMN1; SMN2 | |
| SCHEMBL14100367 | 0.84 | CXCR1 (0.45) | CXCR1CXCR2 | |
| SCHEMBL13208604 | 0.83 | CXCR1 (0.53) | CXCR1CXCR2 | |
| SCHEMBL13208443 | 0.83 | CXCR1 (0.44) | CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1694659-B1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | CXCR1 4/4885CXCR2 6/4885KMT2A 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.